AR126387A1 - ANTI-TNFR2 ANTIBODIES AND USES OF THESE - Google Patents
ANTI-TNFR2 ANTIBODIES AND USES OF THESEInfo
- Publication number
- AR126387A1 AR126387A1 ARP220101767A ARP220101767A AR126387A1 AR 126387 A1 AR126387 A1 AR 126387A1 AR P220101767 A ARP220101767 A AR P220101767A AR P220101767 A ARP220101767 A AR P220101767A AR 126387 A1 AR126387 A1 AR 126387A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- lcvr
- hcvr
- sequence
- chain variable
- Prior art date
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 12
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 12
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 101100425757 Homo sapiens TNFRSF1B gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 abstract 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La invención proporciona anticuerpos monoclonales y fragmentos de unión a antígenos de estos, específicos para TNFR2, y métodos para usarlos para tratar el cáncer o trastornos autoinmunitarios, inclusive politerapias con antagonistas del punto de control inmunitario PD1 / PD-L1. Reivindicación 1: Un anticuerpo monoclonal aislado, o un fragmento de unión al antígeno de este, caracterizado porque dicho anticuerpo monoclonal o fragmento de unión al antígeno de este es específico para TNFR2 humano, y en donde dicho anticuerpo monoclonal comprende: (1a) una región variable de cadena pesada (HCVR), que comprende una secuencia de HCVR CDR1 de la SEQ ID Nº 1, una secuencia de HCVR CDR2 de la SEQ ID Nº 2, y una secuencia de HCVR CDR3 de la SEQ ID Nº 3; y, (1b) una región variable de cadena ligera (LCVR), que comprende una secuencia de LCVR CDR1 de la SEQ ID Nº 4, una secuencia de LCVR CDR2 de la SEQ ID Nº 5, y una secuencia de LCVR CDR3 de la SEQ ID Nº 6; o, (2a) una región variable de cadena pesada (HCVR), que comprende una secuencia de HCVR CDR1 de la SEQ ID Nº 14, una secuencia de HCVR CDR2 de la SEQ ID Nº 15 y una secuencia de HCVR CDR3 de la SEQ ID Nº 16; y (2b) una región variable de cadena ligera (LCVR), que comprende una secuencia de LCVR CDR1 de la SEQ ID Nº 17, una secuencia de LCVR CDR2 de la SEQ ID Nº 18 y una secuencia de LCVR CDR3 de la SEQ ID Nº 19; o (3a) una región variable de cadena pesada (HCVR), que comprende una secuencia de HCVR CDR1 de la SEQ ID Nº 26, una secuencia de HCVR CDR2 de la SEQ ID Nº 27 y una secuencia de HCVR CDR3 de la SEQ ID Nº 28; y (3b) una región variable de cadena ligera (LCVR), que comprende una secuencia de LCVR CDR1 de la SEQ ID Nº 29, una secuencia de LCVR CDR2 de la SEQ ID Nº 30 y una secuencia de LCVR CDR3 de la SEQ ID Nº 31; o (4a) una región variable de cadena pesada (HCVR), que comprende una secuencia de HCVR CDR1 de la SEQ ID Nº 39, una secuencia de HCVR CDR2 de la SEQ ID Nº 40 y una secuencia de HCVR CDR3 de la SEQ ID Nº 41; y (4b) una región variable de cadena ligera (LCVR), que comprende una secuencia de LCVR CDR1 de la SEQ ID Nº 42, una secuencia de LCVR CDR2 de la SEQ ID Nº 43 y una secuencia de LCVR CDR3 de la SEQ ID Nº 44; o (5a) una región variable de cadena pesada (HCVR), que comprende una secuencia de HCVR CDR1 de la SEQ ID Nº 51, una secuencia de HCVR CDR2 de la SEQ ID Nº 52 y una secuencia de HCVR CDR3 de la SEQ ID Nº 53; y (5b) una región variable de cadena ligera (LCVR), que comprende una secuencia de LCVR CDR1 de la SEQ ID Nº 54, una secuencia de LCVR CDR2 de la SEQ ID Nº 55 y una secuencia de LCVR CDR3 de la SEQ ID Nº 56; o (6a) una región variable de cadena pesada (HCVR), que comprende una secuencia de HCVR CDR1 de la SEQ ID Nº 63, una secuencia de HCVR CDR2 de la SEQ ID Nº 64 y una secuencia de HCVR CDR3 de la SEQ ID Nº 65; y (6b) una región variable de cadena ligera (LCVR), que comprende una secuencia de LCVR CDR1 de la SEQ ID Nº 66, una secuencia de LCVR CDR2 de la SEQ ID Nº 67 y una secuencia de LCVR CDR3 de la SEQ ID Nº 68. Reivindicación 42: Un polinucleótido caracterizado porque codifica la cadena pesada o la cadena ligera o la parte de unión al antígeno de esta de cualquiera de las reivindicaciones 1 - 21. Reivindicación 44: Un vector caracterizado porque comprende el polinucleótido de la reivindicación 42 o 43.The invention provides monoclonal antibodies and antigen-binding fragments thereof, specific for TNFR2, and methods of using them to treat cancer or autoimmune disorders, including polytherapies with PD1/PD-L1 immune checkpoint antagonists. Claim 1: An isolated monoclonal antibody, or an antigen-binding fragment thereof, characterized in that said monoclonal antibody or antigen-binding fragment thereof is specific for human TNFR2, and wherein said monoclonal antibody comprises: (1a) a region heavy chain variable (HCVR), comprising an HCVR CDR1 sequence of SEQ ID NO: 1, an HCVR CDR2 sequence of SEQ ID NO: 2, and an HCVR CDR3 sequence of SEQ ID NO: 3; and, (1b) a light chain variable region (LCVR), comprising an LCVR CDR1 sequence of SEQ ID NO: 4, an LCVR CDR2 sequence of SEQ ID NO: 5, and an LCVR CDR3 sequence of SEQ ID No. 6; or, (2a) a heavy chain variable region (HCVR), comprising an HCVR CDR1 sequence of SEQ ID NO: 14, an HCVR CDR2 sequence of SEQ ID NO: 15 and an HCVR CDR3 sequence of SEQ ID No. 16; and (2b) a light chain variable region (LCVR), comprising an LCVR CDR1 sequence of SEQ ID NO: 17, an LCVR CDR2 sequence of SEQ ID NO: 18, and an LCVR CDR3 sequence of SEQ ID NO: 19; or (3a) a heavy chain variable region (HCVR), comprising an HCVR CDR1 sequence of SEQ ID NO: 26, an HCVR CDR2 sequence of SEQ ID NO: 27, and an HCVR CDR3 sequence of SEQ ID NO: 28; and (3b) a light chain variable region (LCVR), comprising an LCVR CDR1 sequence of SEQ ID NO: 29, an LCVR CDR2 sequence of SEQ ID NO: 30, and an LCVR CDR3 sequence of SEQ ID NO: 31; or (4a) a heavy chain variable region (HCVR), comprising an HCVR CDR1 sequence of SEQ ID NO: 39, an HCVR CDR2 sequence of SEQ ID NO: 40, and an HCVR CDR3 sequence of SEQ ID NO: 41; and (4b) a light chain variable region (LCVR), comprising an LCVR CDR1 sequence of SEQ ID NO: 42, an LCVR CDR2 sequence of SEQ ID NO: 43, and an LCVR CDR3 sequence of SEQ ID NO: 44; or (5a) a heavy chain variable region (HCVR), comprising an HCVR CDR1 sequence of SEQ ID NO: 51, an HCVR CDR2 sequence of SEQ ID NO: 52, and an HCVR CDR3 sequence of SEQ ID NO: 53; and (5b) a light chain variable region (LCVR), comprising an LCVR CDR1 sequence of SEQ ID NO: 54, an LCVR CDR2 sequence of SEQ ID NO: 55, and an LCVR CDR3 sequence of SEQ ID NO: 56; or (6a) a heavy chain variable region (HCVR), comprising an HCVR CDR1 sequence of SEQ ID NO: 63, an HCVR CDR2 sequence of SEQ ID NO: 64, and an HCVR CDR3 sequence of SEQ ID NO: 65; and (6b) a light chain variable region (LCVR), comprising an LCVR CDR1 sequence of SEQ ID NO: 66, an LCVR CDR2 sequence of SEQ ID NO: 67, and an LCVR CDR3 sequence of SEQ ID NO: 68. Claim 42: A polynucleotide characterized in that it encodes the heavy chain or the light chain or the antigen-binding part thereof of any of claims 1 - 21. Claim 44: A vector characterized in that it comprises the polynucleotide of claim 42 or 43.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219175P | 2021-07-07 | 2021-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126387A1 true AR126387A1 (en) | 2023-10-11 |
Family
ID=84800439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101767A AR126387A1 (en) | 2021-07-07 | 2022-07-06 | ANTI-TNFR2 ANTIBODIES AND USES OF THESE |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4367140A1 (en) |
| KR (1) | KR20240032985A (en) |
| CN (1) | CN117980336A (en) |
| AR (1) | AR126387A1 (en) |
| AU (1) | AU2022308421A1 (en) |
| CA (1) | CA3224693A1 (en) |
| TW (1) | TW202309096A (en) |
| WO (1) | WO2023281313A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023228082A1 (en) * | 2022-05-26 | 2023-11-30 | Pfizer Inc. | Anti-tnfr2 antibodies and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190135929A1 (en) * | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| EP3707163A4 (en) * | 2017-11-09 | 2021-08-18 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| EP3853252A1 (en) * | 2018-09-18 | 2021-07-28 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| WO2020180712A1 (en) * | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| KR20220038766A (en) * | 2019-08-02 | 2022-03-29 | 장쑤 심시어 파마슈티컬 컴퍼니 리미티드 | Anti-TNFR2 antibodies and uses thereof |
| US20220372154A1 (en) * | 2019-09-17 | 2022-11-24 | Apexigen, Inc. | Anti-tnfr2 antibodies and methods of use |
| CN112480259B (en) * | 2021-02-05 | 2021-05-04 | 百奥赛图(北京)医药科技股份有限公司 | anti-TNFR 2 antibodies and uses thereof |
-
2022
- 2022-07-06 EP EP22837100.1A patent/EP4367140A1/en active Pending
- 2022-07-06 TW TW111125395A patent/TW202309096A/en unknown
- 2022-07-06 KR KR1020247004535A patent/KR20240032985A/en unknown
- 2022-07-06 WO PCT/IB2022/000409 patent/WO2023281313A1/en active Application Filing
- 2022-07-06 CA CA3224693A patent/CA3224693A1/en active Pending
- 2022-07-06 AU AU2022308421A patent/AU2022308421A1/en active Pending
- 2022-07-06 CN CN202280060055.4A patent/CN117980336A/en active Pending
- 2022-07-06 AR ARP220101767A patent/AR126387A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022308421A1 (en) | 2024-01-25 |
| WO2023281313A1 (en) | 2023-01-12 |
| CN117980336A (en) | 2024-05-03 |
| EP4367140A1 (en) | 2024-05-15 |
| KR20240032985A (en) | 2024-03-12 |
| CA3224693A1 (en) | 2023-01-12 |
| TW202309096A (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (en) | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES | |
| PE20231067A1 (en) | ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND THEIR USES | |
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| PE20210132A1 (en) | ANTI-CD3 ANTIBODIES AND USES OF THEM | |
| AR106991A1 (en) | NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
| PE20181089A1 (en) | HUMAN ANTI-CD19 ANTIBODIES WITH HIGH AFFINITY | |
| AR109715A1 (en) | ANTI-CD27 ANTIBODIES | |
| EA202190138A1 (en) | ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE | |
| PH12021550041A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
| CR20220078A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| AR126387A1 (en) | ANTI-TNFR2 ANTIBODIES AND USES OF THESE | |
| PE20211293A1 (en) | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES | |
| AR096601A1 (en) | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE | |
| MX2022007231A (en) | Anti-mertk antibodies and methods of use thereof. | |
| EA202190235A1 (en) | ANTIBODIES TO CD33 AND METHODS OF THEIR APPLICATION | |
| AR109683A1 (en) | ANTIBODIES AGAINST FACTOR XI AND ITS USES | |
| AR115192A1 (en) | ANTIBODIES | |
| MX2021000933A (en) | Anti-siglec-5 antibodies and methods of use thereof. | |
| MX2022012182A (en) | Methods of use of anti-trem2 antibodies. | |
| MX2021015212A (en) | Anti-sortilin antibodies for use in therapy. | |
| MX2022005949A (en) | Anti-ror-2 antibodies and methods of use. | |
| MX2018013523A (en) | Dna monoclonal antibodies targeting il-6 and cd126. | |
| AR123671A1 (en) | ANTI-HUMAN FN14 ANTIBODY | |
| MX2020013172A (en) | Anti-siglec-7 antibodies and methods of use thereof. | |
| AR126971A1 (en) | COMPOSITIONS AND METHODS FOR TREATING LONG QT SYNDROME |